Biogen vs Hermes Robotics

Side-by-side comparison of AI visibility scores, market position, and capabilities

Biogen leads in AI visibility (91 vs 43)

Biogen

LeaderHealthcare Tech

Enterprise

Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.

AI VisibilityBeta
Overall Score
A91
Category Rank
#129 of 290
AI Consensus
84%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
93
Gemini
96

About

Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.

Full profile

Hermes Robotics

EmergingManufacturing

General

Autonomous mobile robot company for warehouse automation; flexible AMR-based fulfillment systems that adapt to changing product mixes without fixed infrastructure.

AI VisibilityBeta
Overall Score
C43
Category Rank
#1040 of 1167
AI Consensus
60%
Trend
stable
Per Platform
ChatGPT
46
Perplexity
43
Gemini
41

About

Hermes Robotics is an autonomous mobile robot (AMR) and warehouse automation company developing robots and software for logistics and fulfillment operations in warehouses, distribution centers, and manufacturing facilities. The company builds ground-based autonomous robots capable of transporting goods, fulfilling orders, and navigating dynamic warehouse environments alongside human workers, with software for fleet management and warehouse orchestration.

Full profile

AI Visibility Head-to-Head

91
Overall Score
43
#129
Category Rank
#1040
84
AI Consensus
60
stable
Trend
stable
99
ChatGPT
46
93
Perplexity
43
96
Gemini
41
99
Claude
34
95
Grok
52

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.